Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG director George Simeon received a grant of stock options for 13,000 common shares. The options carry an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market trade.
According to the vesting terms, the options vest in 12 equal monthly installments, subject to his continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Ali Behbahani received a new stock option grant covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They were awarded as compensation rather than bought on the open market.
According to the vesting terms, the options vest in 12 equal monthly installments, with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual meeting.
CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share. These options were awarded as compensation, not through open-market buying or selling.
According to the vesting terms, the 13,000 options will vest in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 Annual Meeting, assuming she continues to provide service to the company or its subsidiaries.
CRISPR Therapeutics AG reported that director Harold Edward Fleming received a grant of stock options covering 13,000 common shares. The options have an exercise price of 51.84 per share and expire on June 5, 2036. Subject to continued service, they vest in 12 equal monthly installments, beginning with the first installment on June 30, 2026 and the last on the earlier of the one-year anniversary of the grant date or the 2027 annual meeting.
CRISPR Therapeutics AG director John Greene received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the vesting terms, the award vests in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Katherine A. High received a grant of 13,000 stock options on Common Shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They vest in 12 equal monthly installments, beginning June 30, 2026, subject to continued service, with final vesting on the earlier of the one-year anniversary of grant or the 2027 Annual Meeting.
CRISPR Therapeutics AG reported that director Sandesh Mahatme received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the terms, the award vests in 12 equal monthly installments, subject to continued service, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting. This is a compensation-related award rather than an open-market purchase or sale.
CRISPR Therapeutics AG director Morrison Briggs received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the vesting terms, the options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Christian Rommel received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market purchase or sale.
According to the vesting terms, the options will vest and become exercisable in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting, subject to his continued service.
CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant covering 13,000 common shares. The option has an exercise price of $51.84 per share and was awarded at no purchase cost to him on the grant date.
The option expires on June 5, 2036. According to the vesting terms, it becomes exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026 and the final installment vesting on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.